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Our paper presents a prac t ica l app l i ca t ion of the mathemat i -
ca l model o f d ig i ta l i s pharmacokinet ics as the f i rst step towards the 
a lgor i thmiza t ion of d ig i ta l i s der ivat ives therapy. The paper presents 
the results o f a computer program wr i t ten for the op t ima l i za t ion of 
f i v e d ig i ta l i s der ivat ives (oral and intravenous therapy), based on 
the mathematical descr ipt ion of d ig i ta l i s -g lycos ide k inet ics in patients 
w i t h normal and reduced renal func t ion . We appl ied f i ve der ivat ives, 
character ized by d i f fe rent dynamics of their resorption and excret ion 
a f te r oral dosage and by d i f fe ren t metabo l i c , especia l ly in t rahepat ic , 
i nac t i va t ion patterns. One of the basic d i f f i cu l t i es in therapy is 
connected w i t h changing the dosage when a par t icu lar cardiac g l y c o -
side is replaced by an other one of d i f fe rent pharmacokinet ic - charac-
ter is t ics. This may lead to tox ic reactions because the total glycoside 
concent ra t ion is unknown. Mathemat ica l descr ipt ion of glycoside k i n e -
t ics is very he lpfu l i n the management of._-various kinds of cardiac 
insu f f i c iency . 
. The paper presents the t ime-shared computer program to formu-
late dosage regimens of f i ve d ig i ta l i s der ivat ives. The computer prog-
ram takes into account f i ve der i va t i ves : 1. D igox in , 2 . Lanatosid C , 
3 . Strophant in, 4 . Prosci l lar id in A , 5 . A c e t y l o d i g i t o x i n . Our deta i led 
computer program for d ig i ta l i s dosage was elaborated by Krystyna 
Domzal and Jan Domzal in the Cybernet ics and Informatics Department 
o f the Universi ty of L6dz (Poland), based on the method described by 
J e l l i f f e (5,6) in Ca l i f o rn ia . J e l i f f e ' s (5 ,6 ) computer program was based 
on numerous experiments and c l i n i c a l observations which showed that the 
* This report is supported by Computat ion Centre of the Polish Academy 
o f Sciences. 
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serum concentrat ion of t r i t i a ted d i g o x i n or d i g i t o x i n and the g lycos ide 
loss from the body were prport ional to the oral dose. The h a l f - l i f e o f 
t r i t ia ted glycosides is similar in l i v e r , kidneys and myocardium a f te r 
the cessation of the drug. The glycosides are then e l im ina ted f rom the 
body in a logar i thmic manner. J e l i f f e (3) described that the average 
rate-constant for a l l body losses for d i g i t o x i n is 0 . 1 1 5 5 day "^ and for 
d igox in 0 . 4 3 3 2 day . The value o f h a l f - t i m e of d i g o x i n in pat ien ts 
w i t h normal renal func t ion is 1.6 day and the tota l body losses r a t e -
-constant is 0 . 4 3 3 2 day"^ and this is the sum of faecal losses r a t e -
-constant k r = 0 .1690 day"^ plus the ur ine losses ra te-constant k = 
- 1 . . . . U 
= 0 .2642 day . D igox in and Lanatosid C k inet ics are p ro found ly a f -
fected by al terat ions in the pa t ien t ' s renal f u n c t i o n , a n d the average 
ha l f - t ime of d igox in found 1 .6 day by normal renal f u n c t i o n increases 
to 4 . 1 days in anur ic pat ients. The a l t e ra t i on o f d i g i t o x i n u r inary los-
ses in anur ic patients increases the h a l f - t i m e f rom 6 . 0 days in normal 
pat ients to 8 . 6 5 days in anuric pat ien ts . The va lue of tota l body los-
ses rate-constant for d ig i t ox in is 0 . 1 1 5 5 and this is the sum of f aeca l 
losses rate constant k r = 0 .0801 and the ur ine losses ra te -cons tan t k = 
f u 
= 0 . 0 3 5 4 . The urine loss rate-constant of d igox in and d i g i t o x i n are 
proport ional to the serum and urine concentrat ions and this enables to 
compute the ha l f - t ime for d igox in and d i g i t o x i n , based on ac tua l serum 
and urine concentrat ions. A f te r d i g i t o x i n loading the average ur ine loss 
is 30 .6 % of the da i l y loss, 6 1 . 6 % is the d a i l y nonur inary loss, and 
7,7 % o f d a i l y loss is dependent on the metabol ic conversion of d i g i -
tox in to d i g o x i n . O n the cont rary , the urine loss of d i g o x i n is 59 % , 
and nonurinary loss, dependent on the enzymat ic in t rahepat ic i n a c t i v a -
t ion , is 41 % (4). 
In our computer program for d ig i ta l i s dosage we have i n c o r p o r a -
ted the average values of d igox in resorpt ion g iven by many authors (8) 
as 81 % , in contrast to J e l l i f f e ' s ( 5 , 6 ) program (85 % ) , and we i n c l u -
ded the average Lanatosid C resorption 42 % / o m i t t e d in the program 
described by Je l l i f f e ( 5 , 6 ) / . The next mod i f i ca t ion o f the program was 
the inclusion of the values of the A c e t y l o d i g i t o x i n 8 0 % and of Prosc i l -
la r id in 25 % after an oral dose. The inc lus ion of new drugs led to the 
next modi f ica t ion / u s i n g the values described by Krau twa ld ( 7 ) / , 
namely we have incorporated the f o l l o w i n g values of d a i l y losses: 
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A c e t y l o d i g i t o x i n 
Prosci l lar id in A 
Strophantin 
Lanatosid C 
In our program we included the inf luence of a l tered renal 
f u n c t i o n based on blood urea concentrat ion and we computed to ta l 
constant rate of d a i l y d igox in losses ( K ) using the method of least 
squares: 
K = 0 .1155 - In 0 . 6 9 9 + 0 . 2 0 5 ^ , / l / 
In o 
n = blood urea concent ra t ion. 
The computer program for d ig i ta l i s dosage is appropriate o n -
ly for patients w i th normal thyroid and hepat ic func t ion and normal 
e lec t ro ly te ba lance, (especial ly ka l ium) and for patients w i thou t 
c l i n i c a l evidence of gastrointestinal malabsorpt ion. The patients must 
not be treated w i t h drugs a l te r ing d ig i ta l i s absorption or metabolism. 
Enclosed we present the abbreviated pr in tout from the Polish 
computer " 0 d r a - 1 3 0 4 " . Our de ta i led program was wr i t ten in FORT-
R A N . Its various app l ica t ions , inc lud ing the possibi l i t ies of r e p l a c -
ing one cardiac glycoside by another , are i l lustrated here on a 
single example. A pat ient was g iven Lanatosid C parentera l ly f o l l owed 
by ora l administrat ion of d igox in in changing doses and at d i f fe ren t 
i n t e r v a l s . The total body glycoside concentrat ion in micrograms of 
g lycoside per ki logramme of body weight is computed as the f i rst part 
o f the computer program. Af te r the total body glycoside concentrat ion 
is computed, the physician selects its opt imal level comparing the f o r -
mer and actual state of the pa t ien t . The computer prints out stat is t ical 
data about d ig i ta l i s t o x i c i t y f requency, accord ing to various levels of 
to ta l body glycoside concent ra t ion. St i l l the next change in our p r o -
gram comparing to J e l l i f f e ' s (5 ,6) one is the lower t ox i c i t y warning 
threshold. Our select ion of glycoside level over 13 .0 m c g / k g , reminds 
that the tox ic i t y risk exceeds 21 % . The computer operator must then 
enter the selected inputs three times, before the computer accepts them. 
The last mod i f i ca t ion in our program enables us the achievement 
o f the desired total dose in four versions: in one, two, three or four 
- 10 % d a i l y losses from the total body concentrat ion 
- 50 % - " -
- 40 % - " - " -
- 2 0 % - " " -
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days. O w i n g to this, the selection of the opt imal method of the necessa-
ry body glycosides concentrat ion can be done . 
The app l i ca t i on of computer program in d ig i t a l i s therapy based on 
average values of f i ve der ivat ives ' k ine t i cs .makes the t reatment more 
precise. Its prac t ica l value is most prominent in the reduct ion of d i g i t a -
lis t o x i c i t y f requency. In our Internal M e d i c i n e Department 29 % tox i c 
reactions were observed before employing the computer , the number o f 
wh ich was then s ign i f i can t ly reduced to 14 % ( 1 , 2 ) . The main adventage 
of our program is the possib i l i ty of everyday cont ro l of tota l serum g l y c o -
side concentrat ion wi thout drawing blood a f te r each d ig i t a l i s dose. The 
program has also d idac t i c values in teaching cont ro l led d ig i t a l i s t he rapy . 
We have studied the accuracy of our program in 72 inpat ients and 
we stated that the program enables us to have more precise d i g i t a l i s t h e -
rapy and reduces the frequency of tox ic react ions. 
We have compared in 32 pat ients the computed d i g o x l n c o n c e n t r a -
t ion to serum d igox in level determined by radioimmunoassay acco rd ing to 
Sheiner and Rosenberg (9). The abundant l i te ra ture concern ing the metodo-
logies involved w i th the radioimmunoassay of serum d igox in concent ra t ions 
indicates that there are many problems associated w i t h a c c u r a c y , rep rodu-
c i b i l i t y and comparab i l i ty of results. The numerous procedural mod i f i ca t ions 
alone ind icate dissatisfaction among the proponents of the various methods. 
The various methods wh ich have been proposed, and the c o n f l i c t i n g data 
obtained in many laboratories lead to the conc lus ion, that when compar ing 
the computed data to evaluated da ta , the data rece ived by computer p r o g -
ram, based on many pharmacokinet ic f ind ings are more accura te for con -
stant control of d ig i ta l i s therapy. The computed values are in close c o n n e c -
t ion w i t h pa t ien ts ' f ind ings , such as heart ra te , e lec t rocard iog raphy , b lood 
urea concentrat ion and magnesium and ka l ium plasma concent ra t ions . The 
control of serum d igox in concentrat ion cou ld not be performed eve ry day 
and the computed values can be obta ined af ter each dose and therefore are 
much simpler for permenent control of d ig i t a l i s therapy, tak ing in to accoun t 
f i ve der ivat ives, wh i le the radioimmunoassay method enables us to determine 
on ly d i g i t o x i n and d igox in . The isotopic methods using stront ium j l ^ l s h o w -
ed less accuracy than the radioimmunoassay method, however they might 
be used to determine a l l cardiac .glycosides. In our ac tua l exper ience the 
mathematical model of pharmacokinet ics of d i g i t a l i s g lycos ide is much more 
exact in everyday physic ian pract ice than the laboratory f ind ings regarded 
to serum d ig i ta l i s concentrat ion in considerat ion of great labora tory e r ro r . 
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A N EXAMPLE OF PRINTOUT OF THE DIGITALIS THERAPY P R O G -
RAM COMPUTER PROGRAM FOR DIGITALIS THERAPY 
Name Number 
Previous d ig i ta l i s therapy? Yes. 
Fixed dose? N o 
Body w e i g h t : 52 .00 
Enter number of changed doses: 22 
Enter for every changed dose: dose, drug (Ace td ig l t , Dox, Lanat, 
Stroph, Prosci l l ) 
Route (oral = 0 , parenteral = p ) , 
Blood ures, hours between doses 
Dose Drug Route Ures Hours 
0 . 8 0 0 L A N A T P 4 9 . 7 0 2 4 . 0 
0 . 2 0 0 L A N A T P 4 9 . 7 0 12.0 
0 . 2 0 0 L A N A T P 4 9 . 7 0 12.0 
0 . 2 0 0 L A N A T P 4 9 . 7 0 12 .0 
0 . 2 0 0 L A N A T P 4 9 . 7 0 12.0 
0 . 2 0 0 L A N A T P 4 9 . 7 0 12.0 
0 . 2 0 0 L A N A T P 4 9 . 7 0 12.0 
0 . 2 5 0 DOX 0 4 9 . 7 0 2 4 . 0 
0 . 2 5 0 DOX 0 4 9 . 7 0 24 .0 
0 . 2 5 0 DOX 0 103.00 2 4 . 0 
0 . 2 5 0 DOX 0 103.00 2 4 . 0 
0 . 2 5 0 DOX 0 103.00 2 4 . 0 
0 . 2 5 0 DOX 0 103.00 24 .0 
0 . 2 5 0 DOX 0 103.00 2 4 . 0 
0 . 2 5 0 DOX 0 103.00 24 .0 
0 . 2 5 0 DOX 0 103.00 2 4 . 0 
0 . 2 5 0 DOX 0 103.00 2 4 . 0 
0 . 2 5 0 DOX 0 103.00 24 .0 
0 . 2 5 0 DOX 0 68 .00 24 .0 
0 . 2 5 0 DOX 0 68 .00 2 4 . 0 
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C A L C . B O D Y GLYCOSIDE C O N C E N T R . A T B E G I N N I N G A N D E N D 
OF EACH DOSE 
. . i * .. . i pa p r n -i Total body Total body 
Number A c e t d i q i t L a n a t - D o x Strof Proscil x ' „ 
° , . concent(mq) concen t m c q / k q 
beg end , j L j ** beg end beg end 
C.OCO 0 . 0 0 0 0 . 8 0 0 0 . 6 4 0 15 .385 1 2 . 3 0 8 
0 .000 0 . 0 0 0 0 . 8 4 0 0 . 7 5 1 16 .154 1 4 . 4 4 8 
0 .000 0 . 0 0 0 0 . 9 5 1 0 . 8 5 1 18 .295 1 6 . 3 6 3 
0 .000 0 . 0 0 0 1.051 0 . 9 4 0 2 0 . 2 0 9 1 8 . 0 7 6 
0 .000 0 . 0 0 0 1 .140 1 .020 2 1 . 9 2 2 1 9 . 6 0 8 
0 .000 0 . 0 0 0 1 .200 1 .091 2 3 . 4 5 5 2 0 . 9 7 8 
O.OCO 0 . 0 0 0 1.291 1 .155 2 4 . 8 2 4 2 2 . 2 0 3 
0 .000 0 . 0 0 0 1 .357 1 .049 2 6 . 0 9 7 2 0 . 1 8 3 
0 .000 0 . 0 0 0 1 .252 0 . 9 4 3 2 4 . 0 7 7 1 8 . 1 3 4 
0 .000 0 . 0 0 0 1 .145 0 . 8 9 1 2 2 . 0 2 8 1 7 . 1 3 7 
0 .000 0 . 0 0 0 1 .094 0 . 0 9 4 2 1 . 0 3 1 1 6 . 2 2 4 
0 .000 0 . 0 0 0 1 .046 0 . 8 0 1 2 0 . 1 1 9 15 .410 
0 .000 0 . 0 0 0 1 .004 0 . 7 6 4 19 .304 1 4 . 6 9 6 
0 .000 0 . 0 0 0 0 . 9 6 7 0 . 7 3 2 18 .590 14.079 
0 .000 0 . 0 0 0 0 . 9 3 5 0 . 7 0 5 17 .973 13 .551 
O.OCO 0 . 0 0 0 0 . 9 0 7 0 . 6 8 1 17 .445 13 .103 
0 .000 0 . 0 0 0 0 . 8 8 4 0 . 6 6 2 1 6 . 9 9 8 1 2 . 7 2 7 
0 . 0 0 0 0 . 0 0 0 0 . 8 6 4 0 . 6 4 5 16 .621 12 .412 
0 . 0 0 0 0 . 0 0 0 0 . 8 4 8 0 . 5 8 2 1 6 . 3 0 7 11 .196 
0 . 0 0 0 0 . 0 0 0 0 . 7 8 5 0 . 5 3 7 15 .090 10 .329 
0 . 0 0 0 0 . 0 0 0 0 . 7 4 0 0 . 5 0 5 14 .224 9 . 7 0 8 
0 . 0 0 0 0 . 0 0 0 0 . 7 0 7 0 . 4 8 2 13 .603 9 . 2 6 0 
Total glycoside concentr . a t your next dose should b e : 
0 . 4 8 mg 9 . 2 6 0 m e g / k g 
No te the fo l l ow ing data: 
Total body concent r . ( m c g / k g ) Incidence of d i g i t arrythmias 
8 . 5 13 % 
dose beg end beg end 
1 0 . 0 0 0 0 .000 0 . 8 0 0 0 .640 
2 0 .000 0 .000 0 .840 0 .751 
3 0 .000 0 . 0 0 0 0 .951 0 .851 
4 0 .000 0 .000 0 .051 0 .940 
5 0 . 0 0 0 0 .000 1 .140 1.020 
6 0 . 0 0 0 0 .000 1.220 1.091 
7 0 .000 0 .000 1.291 1.155 
8 0 . 0 0 0 0 .000 1 .357 1.049 
9 0 .000 0 .000 1.252 0 .943 
10 0 .000 0 .000 1.145 0 .891 
11 0 .000 0 .000 1.094 0 .844 
12 C.000 0 . 0 0 0 1.046 0 .801 
13 0 .000 0 .000 1.004 0 . 7 6 4 
14 0 .000 0 .000 0 . 9 6 7 0 .732 
15 0 .000 0 . 0 0 0 0 .935 0 .705 
16 0 .000 0 .000 0 . 9 0 7 0.681 
17 0 .000 0 .000 0 . 8 8 4 0 .662 
18 0 .000 0 .000 0 . 8 6 4 0 .645 
19 0 . 0 0 0 0 . 0 0 0 0 . 8 4 8 0 .582 
20 0 . 0 0 0 0 .000 0 . 7 8 5 0 . 5 3 7 
21 0 .000 0 .000 0 . 7 4 0 0 . 5 0 5 
22 0 .000 0 .000 0 . 7 0 7 0 .482 
13 .0 21 to 




2 5 . 0 42 % 
Concent r .over 3 5 . 0 m c g / k g may be l e t h a l ! 
Enter desired concent r . ( m c g / k g ) , Blood ures and body w e i g h t (kg) 
2 5 . 0 6 8 . 0 0 5 0 . 0 0 
Risk of t o x i c i t y is 4 2 . 0 % 
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Retype input 
25.0 68.00 50.00 
Retype input 
25.0 68.00 50.00 
Retype input 
25.0 68.00 50.00 
Enter drug (Acetdigit, Dox, Lanat, Stroph, Proscill), Route (0,P) , Doses day 
Lanat 0 2 
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Version 1 
Desired concentration wil l be achieved in one day. 
To achieve and maintain your selected concentration with your chosen 
glycoside and route, the following dose program is suggested, if renal 
function and electrolyte balance do not change. 
Day Number of dose Dose in mg Lanat Tabs of 0.25 mg Number of drops 
Lanat 
1 0.91 3.66 32.9 
2 1.21 4.84 43.6 
1 0.38 1.51 13.6 
2 0.37 1.47 13.2 
1 0.36 1.43 12.9 
2 0.35 1.40 12.6 
1 0.34 1.37 12.4 
2 0.34 1.35 12.2 
1 0.33 1.33 12.0 
2 0.33 1.32 11.9 
1 0.33 1.31 11.7 
2 0.32 1.30 11.7 
1 0.32 1.29 11.6 
2 0.32 1.29 11.6 
Version 2 in drops 
16.5, 25.4, 26.6, 27.9, 12.9, 12.6, 12.4, 12.2, 12.0, 11.9, 11.8, 
11.7, 11.6, 11.6. 
Version 3 in drops 
11.0, 19.3, 20.0, 20.7, 21.5, 22.4, 12.4, 12.2, 12.0, 11.9, 11.8, 
11.7, 11.6, 11.6. 
Version 4 in drops 
8.2, 16.3, 16.7, 17.1, 17.6, 18.2, 18.9, 19.5, 12.0, 11.9, 11.8, 
11.7, 11.6, 11.6. 
52 sec. 
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